27 Aug 2014 15:38
27 August 2014
Silence Therapeutics plc
Notice of half year results - 16 September 2014
Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, will publish its half year results for the six months to 30 June 2014 on Tuesday, 16 September 2014.
A capital markets presentation will be planned for later this calendar year.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Tim Freeborn, Finance Director | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor |
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA interference (RNAi) or 'gene silencing' platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.
Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology. Its platform is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. Silence's RNAi platform has been used in three Phase 2 clinical trials, two awaiting results. It also has a robust IP estate protecting its proprietary technology.